Baird Maintains Outperform on Instil Bio, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen maintains an Outperform rating on Instil Bio (NASDAQ:TIL) but lowers the price target from $54 to $32.
May 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird maintains an Outperform rating on Instil Bio but reduces the price target from $54 to $32.
The reduction in price target by Baird, despite maintaining an Outperform rating, could lead to short-term negative sentiment among investors, potentially impacting the stock's price negatively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100